Vigil Neuroscience (NASDAQ:VIGL) Price Target Raised to $24.00

by · The Cerbat Gem

Vigil Neuroscience (NASDAQ:VIGL – Free Report) had its target price raised by Wedbush from $23.00 to $24.00 in a research report released on Friday morning,Benzinga reports. The firm currently has an outperform rating on the stock.

Several other equities research analysts also recently commented on the stock. Guggenheim decreased their target price on shares of Vigil Neuroscience from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th. HC Wainwright reissued a “buy” rating and set a $17.00 target price on shares of Vigil Neuroscience in a research report on Friday. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Vigil Neuroscience currently has a consensus rating of “Moderate Buy” and an average target price of $16.80.

View Our Latest Stock Report on Vigil Neuroscience

Vigil Neuroscience Price Performance

Shares of NASDAQ VIGL remained flat at $3.57 during trading on Friday. 47,893 shares of the stock traded hands, compared to its average volume of 236,640. The firm has a fifty day moving average of $3.58 and a two-hundred day moving average of $3.63. Vigil Neuroscience has a 52-week low of $2.47 and a 52-week high of $6.98. The firm has a market cap of $141.54 million, a price-to-earnings ratio of -1.68 and a beta of 1.92.

Vigil Neuroscience (NASDAQ:VIGL – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.02. Analysts expect that Vigil Neuroscience will post -2.15 EPS for the current fiscal year.

Institutional Investors Weigh In On Vigil Neuroscience

A number of institutional investors have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. bought a new stake in Vigil Neuroscience in the 2nd quarter worth about $5,940,000. Vanguard Group Inc. grew its position in Vigil Neuroscience by 11.9% in the 1st quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock worth $3,050,000 after purchasing an additional 95,276 shares in the last quarter. Ensign Peak Advisors Inc grew its position in Vigil Neuroscience by 72.8% in the 2nd quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock worth $1,580,000 after purchasing an additional 166,442 shares in the last quarter. abrdn plc bought a new position in shares of Vigil Neuroscience during the 3rd quarter valued at approximately $799,000. Finally, Renaissance Technologies LLC grew its position in shares of Vigil Neuroscience by 19.2% during the 2nd quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock valued at $286,000 after acquiring an additional 11,536 shares during the period. 83.64% of the stock is owned by institutional investors.

About Vigil Neuroscience

(Get Free Report)

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.

Featured Articles